Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus FACTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus FACTIVE.
CIPROFLOXACIN AND DEXAMETHASONE vs FACTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
None Documented
None Documented
Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours.
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites.
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic